Conditions: Epilepsy
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 18
Healthy volunteers: yes

Brief summary:
Single-centre, open-label, randomised, gender-balanced, 3-way crossover, 3-period, 3-sequence study in 18 healthy male and female subjects.

Detailed description:
Single-centre, open-label, randomised, gender-balanced, 3-way crossover, 3-period, 3-sequence study in 18 healthy male and female subjects. The study consisted of 3 periods separated by a washout of 7 days or more between doses. Subjects received a single oral 800 mg dose of eslicarbazepine acetate following a standard meal in one period, and following at least 10 hours of fasting in two periods.

Arms:
arm 1: Tablets 800 mg. Administration:Oral. arm 2: Tablets 800 mg. Administration:Oral. arm 3: Tablets 2 x 400 mg. Administration:Oral.

Interventions: intervention 1: BIA 2-093
Intervention descriptions: intervention 1: None

Protocol document: